

Join us for an informative Speaker Program to learn more about ZUNVEYL®



You're Invited to Discover the Impact of ZUNVEYL in Long-Term Care

Please join us for an educational speaker program to learn more about ZUNVEYL.

Learning Objectives

1. Examine the Impact of Treating Alzheimer's Disease in Long-Term Care (LTC)
2. Explore the Technology and Mechanism of Action of ZUNVEYL
3. Review ZUNVEYL Clinical and Real-World Outcomes
4. Navigate the ZUNVEYL Prior Authorization (PA) Process

Event Details:

RSVP To:

This event is intended for US-licensed healthcare professionals only and is not certified for CME/CE credit.
CE=continuing education; CME=continuing medical education.

INDICATION AND USAGE

ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.

SELECT SAFETY INFORMATION

CONTRAINDICATIONS

ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred.

ADVERSE REACTIONS

The most common adverse reactions with galantamine tablets ($\geq 5\%$) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.

Please see full Prescribing Information available from your presenter for more information about ZUNVEYL.